Headed Up or Down? Pharma's Position in the Current Economy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Headed Up or Down? Pharma's Position in the Current Economy
Results from our annual employment survey.


Pharmaceutical Technology
Volume 33, Issue 12, pp. 30-33

Essential skills, education, training, and knowledge


Figure 10: Respondents job preference.
Respondents with bachelor s and master s degrees are approximately equal in number and each represent about one-third of respondents. At 28.9%, slightly fewer respondents hold doctorates, and a small percentage (4.5%) hold an associate's degree. The most common training was in pharmaceutics or pharmacy, representing 17% of respondents. This was followed by analytical chemistry (14.6%), and fields unrelated to pharmaceutics or science (11%). Over half of respondents were trained in the US (including Puerto Rico), followed by 12.7% trained in the UK, and almost 4% trained in India.


Figure 11: Respondents salary by region.
About one-third of respondents felt their education prepared them extremely well for their current positions, with an additional half feeling their education to have been adequate. Six percent felt their education prepared them poorly for their current positions. In contrast, almost 97% of respondents felt their previous employment experiences prepared them for their current positions.


Figure 12: Attractive job features.
Among the types of knowledge that respondents rate as important in fulfilling their functions, good manufacturing practices (GMPs) came in highest, at 86%. Next in importance is process validation (74%), followed by the US Food and Drug Administration's quality-by-design initiatives (65.8%). Skills that respondents ranked as most important were computer-based systems, including database management (77.8%), chemistry (69.2%), and automation (52.3%). Least important were aseptic processing and isolation technology (40.4%) and biotechnology (46%).


Figure 13: Job seekers least important considerations.
Among regulatory guidelines, respondents are most aware of 21 CFR Part 11, FDA's Rule on Electronic Records and Signatures (91.5%), follwed by 89% who are aware of FDA's "Pharmaceutical CGMPs for the 21st Century." Finally, 80% are aware of FDA's process analytical technology (PAT) guidance for industry. Respondents also report that these regulatory initiatives have changed the manner in which they perform their daily activities at their present jobs in the same order: 21 CFR Part 11 (50.8%), CGMPs (48.4%), and PAT (28%).


Figure 14: Respondents expected job security based on field.


Figure 15: Respondents likelihood of changing jobs this year.


Figure 16: Respondents attitude about feeling valued by employer.


Figure 17: Respondents expectations for future innovation.


Respondents


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here